Gout is a chronic inflammatory disease characterized by swollen joints, pain, heat, redness, and joint stiffness. Gout starts with the inflammation of the big toe; however, it can affect several joints of the body such as ankles, heels, knees, wrists, fingers, and elbows. The disease is caused by the deposition of uric acid crystals in joints resulting in inflammation and pain. Other symptoms include increased level of uric acid in blood, uric acid deposition in joint fluids, and arthritis attacks. Diagnostic tests includes blood tests, synovial fluid testing analysis, and differential diagnosis testing. Treatment of gout includes non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, colchicine-like drugs, and xanthine oxidase inhibitor. Xanthine oxidase inhibitor includes several drugs such as allopurinol and oxypurinol, which reduces uric acid production and helps control gout. According to an article published by the National Center for Biotechnology Information, gout is becoming more prevalent in United States, United Kingdom, New Zealand, and China. Another article published in the Springer Nature stated that the prevalence of this disease is more in developed countries as compared to other areas of the world. It also stated that men are more prone to gout than women. In 2013, gout affected around 5.8 million people, contributing to nearly 1% to 2% of western population. Raising awareness regarding the disease in adult patients could be a profitable marketing opportunity for gout therapy drug manufacturers. The global gout therapy market will be majorly driven by new product launches during the forecast period. Few pipeline drug in the gout therapy market include PF-06743649 by Pfizer and Verinurad by AstraZeneca. Zurampic (lesinurad) by AstraZeneca received U.S regulatory approval in December 2015. The drug is used in combination with xanthine oxidase inhibitor. Entry of new drug therapies such as Uloric, Krystexxa, Colcrys, and Adenuric are expected to fuel the gout therapy market during the forecast period. Development of novel systemic treatment with enhanced safety and efficiency by drug manufactures is expected to boost the gout therapy market. Additionally, steadily rising pool of arthritic patients worldwide could impel the growth of the market.
The global gout therapy market has been segmented based on drug class, distribution channel, and region. Depending on type of drug therapy, the market has been classified into non-steroidal anti-inflammatory drugs, corticosteroids, colchicine-like drugs, xanthine oxidase inhibitor, and others. The Non-steroidal anti-inflammatory drugs are first-line treatment and are considered as a part of therapy, used to reduce pain caused by the inflammation. Colchicine-like drugs are considered to be second-line therapy, used in patients unable to tolerate NSAIDs. Corticosteroids are injected into swollen joints and are as effective as non-steroidal anti-inflammatory drugs. Allopurinol, Probenecid, and Febuxostat are few other drugs used to reduce pain attacks caused by gout. New launch of combination therapy are expected to support the growth of the global gout therapy market. In terms of distribution channel the market has been categorized into hospitals, diagnostic centers, and clinics. Hospitals and clinics are expected to hold more share as compare to diagnostic centers.
Based on geography, the global gout therapy market is segmented into five key regions: Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America and Europe are expected to dominate the market due to higher prevalence of gout in the regions. The Asia Pacific market is projected to hold second highest share in the market owing to rising prevalence of the disease in China and India. China is estimated to account for the largest share of the gout therapeutics market owing to factors such as improvement in diagnosis rate, growing geriatric population, and increasing arthritic patient pool.
Major players involved in the global gout therapy market include AstraZeneca plc., Boehringer Ingelheim GmbH, Teijin Pharma Ltd., Regeneron Pharmaceuticals, GlaxoSmithKline plc., Merck & Co. Inc., Novartis AG, and Savient Pharmaceuticals.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.